Budesonide efficacy and safety in patients with bronchiectasis not due to cystic fibrosis

International Journal of Clinical Pharmacy

Volumn 34, Issue 4, 2012, Pages 644-650

  Hernando, Rosana ^a,b   Drobnic, María Estrella ^a,c   Cruz, María Jesús ^a,c   Ferrer, Adelaida ^a   Suñé, Pilar ^a   Montoro, J Bruno ^a   Orriols, Ramon ^a,c  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b PARC SANITARI SANT JOAN DE DÉU   (Spain)

^c INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Bronchiectasis; Budesonide; Inhaled corticoid

Indexed keywords

BUDESONIDE; INTERLEUKIN 8; PLACEBO;

ADULT; AGED; ARTICLE; BRONCHIECTASIS; CONTROLLED STUDY; COUGHING; CYSTIC FIBROSIS; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EOSINOPHIL; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROBIOLOGY; NONHUMAN; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SPUTUM CYTODIAGNOSIS; SYMPTOMATOLOGY; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; AGED; BRONCHIECTASIS; BUDESONIDE; DOUBLE-BLIND METHOD; FEMALE; FORCED EXPIRATORY VOLUME; GLUCOCORTICOIDS; HUMANS; INTERLEUKIN-8; MALE; QUALITY OF LIFE; SPUTUM; VITAL CAPACITY;

EID: 84867401353     PISSN: 22107703     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11096-012-9659-6     Document Type: Article

References (28)

1. Levine SJ. Bronchial epithelial cell cytokine interactions in airway inflammation. J Investig Med. 1995;43:241-9.
2. Wilson R. The pathogenesis and management of bronchial infections: the vicious cycle of respiratory decline. Rev Contemp Pharmacother. 1992;3:103-12.
3. Derendorf H, Nave R, Drollmann A, Cerasoli F, Wurst W. Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. Eur Respir J. 2006;28:1042-50.
4. From the Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma (GINA) 2010. Available from: http://www.ginasthma.org.
5. From the Global Strategy for the Diagnosis, Management and Prevention of COPD. Global initiative for chronic obstructive lung disease (GOLD) 2010. Available from: http://www.goldcopd.org.
6. King P. Is there a role for inhaled corticosteroids and macrolide therapy in bronchiectasis? Drugs. 2007;67:965-74.
7. Inhaled corticosteroids for cystic fibrosis (Review). The Cochrane collaboration 2009.
8. Inhaled corticosteroids for bronchiectasis (Review). The Cochrane collaboration 2009.
9. Giner J, Basualdo LV, Casan P, Hernandez C, Macián V, Martínez I, et al. Normativa sobre la utilización de fármacos inhalados. Recomendaciones SEPAR. Arch Bronconeumol. 2000;36:34-43.
10. Casals T, Nunes V, Palacio A, Giménez J, Gaona A, Ibáñez N, et al. Cystic fibrosis in Spain: high frequency of mutation G542X in the Mediterranean coastal area. Hum Genet. 1993;91:66-70.
11. Portenoy RK, Thaler HT, Kornblith AB, Lepore JM, Friedlander-Klar H, Kiyasu E, et al. The Memorial Symptom Assessment Scale: an instrument for the evaluation of symptom prevalence, characteristics and distress. Eur J Cancer. 1994;30:1326-36.
12. Ferrer M, Alonso J, Prieto L, Plaza V, Monso E, Marrades R, et al. Validity and reliability of the St George's Respiratory Questionnaire alter adaptation to a different language and culture: the Spanish example. Eur Respir J. 1996;9:1160-6.
13. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J. 2005;26:319-38.
14. Pizzichini E, Pizzichini MM, Efthimiadis A, Hargreave FE, Dolovich J. Measurement of inflammatory indices in induced sputum: effects of selection of sputum to minimize salivary contamination. Eur Respir J. 1996;9(6):1174-80.
15. Murray PR, Washington JA. Microscopic and bacteriologic analysis of expectorated sputum. Mayo Clinic Proc. 1975;50: 339-44.
16. Bauer AW, Kirby WMM, Sherris JC, Turck M. Antibiotic susceptibility testing by a standardized single disk method. Am J Clin Pathol. 1966;45:493-6.
17. Kapur N, Bell S. Kolbe J, Chang AB. Inhaled steroids for bronchiectasis. Cochrane Database Syst Rev. 2009; 1. Art. no.: CD000996. doi:10.1002/14651858. CD000996.pub2.
18. Fuschillo S, De Felice A, Balzano G. Mucosal inflammation in idiopathic bronchiectasis: cellular and molecular mechanisms. Eur Respir J. 2008;31:396-406.
19. Phua GC, Macintyre NR. Inhaled corticosteroids in obstructive airway disease. Respir Care. 2007;52:852-8.
20. Sutherland R, Allmers H, Ayas NT, Venn J, Martin RJ. Inhaled corticosteroids reduce progression of airflow limitation in chronic obstructive pulmonary disease: a meta-analysis. Thorax. 2003;58: 937-41.
21. Escotte S, Tabary O, Dusser D, Majer-Teboul C, Puchelle E, Jacquot J. Fluticasone reduces IL-6 and IL-8 production of cystic fibrosis bronchial epithelial cells via IKK-b kinase pathway. Eur Respir J. 2003;21:574-81.
22. Elborn JS, Johnston B, Allen F, Clarke J, McGarry J, Varguese G. Inhaled steroids in patients with bronchiectasis. Respir Med. 1992;86:121-4.
23. Tsang KWT, Ho PL, Lam WK, Ip MSM, Chan KN, Ho CS, et al. Inhaled fluticasone reduces sputum inflammatory indices in severe bronchiectasis. Am J Respir Crit Care Med. 1998;158: 723-7.
24. Joshi JM, Sundaram P. Role of inhaled steroids in stable bronchiectasis. Indian Pract. 2004;57(4):243-5.
25. Tsang KW, Tan KC, Ho PL, Ooi GC, Ho JC, Mak J, et al. Inhaled fluticasone in bronchiectasis: a 12 month study. Thorax. 2005;60: 239-43.
26. Martínez-García MA, Perpiñá-Tordera M, Román-Sánchez P, Soler-Cataluña JJ, Carratalá A, Pastor M. Inhaled steroids improve quality of life in patients with steady-state bronchiectasis. Respir Med. 2006;100:1623-32.
27. Lionakis MS, Kontoyiannis DP. Glucocorticoids and invasive fungal infections. Lancet. 2003;362:1828-38.
28. Angrill J, Agustí C, de Celis R, Rañó A, Gozalez J, Solé T, et al. Bacterial colonisation in patients with bronchiectasis: microbiological pattern and risk factors. Thorax. 2002;57:15-9.